A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn's Disease.
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2015
At a glance
- Drugs Laquinimod (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 05 Aug 2014 Pharmacokinetic results presented at the Digestive Disease Week 2014.
- 05 Aug 2014 Posthoc results presented at the Digestive Disease Week 2014.
- 21 May 2013 Results presented at the Digestive Disease Week 2013.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History